Convalescent plasma therapy for COVID-19: a tried-and-true old strategy?

Signal Transduct Target Ther. 2020 Sep 15;5(1):203. doi: 10.1038/s41392-020-00310-8.
No abstract available

Publication types

  • Review

MeSH terms

  • Antibodies, Neutralizing / therapeutic use*
  • Antibodies, Viral / therapeutic use*
  • Antibody-Dependent Enhancement / drug effects
  • Antiviral Agents / therapeutic use
  • Betacoronavirus / drug effects
  • Betacoronavirus / immunology
  • Betacoronavirus / pathogenicity
  • COVID-19
  • COVID-19 Serotherapy
  • Complement Pathway, Alternative / drug effects
  • Coronavirus Infections / diagnosis
  • Coronavirus Infections / immunology
  • Coronavirus Infections / mortality
  • Coronavirus Infections / therapy*
  • Cytokine Release Syndrome / diagnosis
  • Cytokine Release Syndrome / immunology
  • Cytokine Release Syndrome / mortality
  • Cytokine Release Syndrome / therapy*
  • Disease Progression
  • Immunization, Passive / methods
  • Lymphopenia / diagnosis
  • Lymphopenia / immunology
  • Lymphopenia / mortality
  • Lymphopenia / therapy*
  • Pandemics
  • Pneumonia, Viral / diagnosis
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / mortality
  • Pneumonia, Viral / therapy*
  • Receptors, IgG / genetics
  • Receptors, IgG / immunology
  • SARS-CoV-2
  • Severity of Illness Index
  • Survival Analysis

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Antiviral Agents
  • Receptors, IgG